What a Business Developer Actually Does in Life Sciences
Updated: Sep 7
The title business developer is used loosely. In some companies it means a salesperson with a longer job description. In life sciences it means something more specific, and confusing the two is why many CROs, CDMOs and biotech service providers hire the wrong person.
This article sets out what a business developer actually owns in a life sciences company, why the role differs from ordinary B2B sales, how to measure one, and when a full-time hire makes sense against a fractional arrangement.
What a business developer owns in life sciences
Four responsibilities define the role. A person who only does the fourth is a salesperson. A person who does all four is a business developer.
1. Defining who the company sells to
Before any outreach, someone has to decide which segments the company pursues, which it declines, and what qualifies or disqualifies an account. In a small provider this is rarely written down, which is why outreach drifts toward whoever replies rather than whoever is worth winning.
A usable ideal client profile names the segment, the company stage, the therapeutic area or modality, and the operational problem you solve. Everything downstream depends on it, as covered in our guide to prospecting for life science consulting firms.
2. Creating conversations that would not have happened
This is the part most often outsourced and most often done badly. It means sourcing named contacts rather than generic inboxes, writing outreach that references the prospect's actual situation, and running it consistently rather than in bursts.
Consistency matters more than intensity in this sector. A biotech program can freeze overnight when a financing round slips. The provider still in contact eight months later is the one that receives the request for proposal when it restarts.
3. Qualifying technically, not just commercially
A generalist qualifies on budget, authority, need and timing. In life sciences that is not enough. The business developer has to establish whether the modality fits the company's capability window, where the program sits in its development path, and which regulatory milestone creates the buying trigger.
This is why scientific fluency is the price of entry. Prospects are scientists and operators, and they can tell within one conversation whether the person across the table understands their scale-up risk and their regulatory path.
4. Holding the relationship through a long cycle
The pharmaceutical B2B sales cycle averages around 138 days, nearly double the 70 day retail average, and complex CRO or CDMO engagements often exceed twelve months. Buying groups commonly run six to thirteen stakeholders.
Someone has to keep that relationship warm across the quiet months, track which stakeholder moved, and know when a technical milestone reopens the conversation. That continuity is the job.
Why the life sciences version of the role is different
The buyer is technical. Outreach written in generic lead generation language does not survive the first exchange with a head of clinical operations or a CMC lead.
The cycle is long and non-linear. Programs pause for funding, for regulatory feedback, for a change of modality. Pipeline gaps have to be diagnosed two to three quarters before they show up in revenue.
The committee is large. Science, operations, quality, procurement and finance all have a view. A champion in one function cannot carry a decision alone.
Capacity planning depends on the forecast. For a CRO or CDMO, knowing what is coming is not only a revenue question, it determines staffing and slot allocation.
What a business developer is not
Not a closer brought in at the end. If the role starts when an opportunity is already qualified, the company has an account executive, not a business developer.
Not the marketing function. Marketing builds demand at the category level. Business development creates specific conversations with named accounts.
Not an account manager. Retaining and growing an existing client is a different discipline from opening a market that does not know you.
Not a list buyer. Volume without relevance is the failure mode that technical buyers punish fastest.
How to measure a business developer
Measuring on closed revenue alone is unfair and uninformative in a market with twelve month cycles. By the time revenue appears, the work that produced it happened three quarters earlier.
Use leading indicators that predict revenue, and review them on a fixed cadence. Teams that track pipeline velocity weekly report around 87 percent forecast accuracy, against roughly 52 percent for teams that monitor inconsistently.
Number of net new named accounts engaged, not emails sent.
Reply rate and, more importantly, the reasons accounts disqualify.
Qualified opportunities created, against an agreed definition of qualified.
Stage-to-stage conversion, to find where opportunities actually stall.
Pipeline coverage against quota, which in life sciences usually needs to sit between three and five times.
Average B2B win rates run around 21 percent across all opportunities and 29 percent for qualified ones, which is what makes coverage math matter. More detail in our guide to pipeline optimization.
The first ninety days of a business developer
Weeks 1 to 4. Learn the capability window in detail. Define or rewrite the ideal client profile. Map the buying committee for the target segment. Build the first target account list.
Weeks 5 to 8. Write positioning and outreach for that segment. Start consistent outbound. Instrument everything so conversion can be measured later.
Weeks 9 to 12. Report on reply and qualification rates, the disqualification reasons, and the first qualified conversations. Adjust the segment or the message based on evidence, not opinion.
Expecting signed revenue in ninety days in this sector is a planning error. Expecting a defined market, a working list and measurable early conversion is reasonable.
Full-time, fractional or outsourced
A full-time hire suits a company with steady, predictable demand and enough volume to keep a senior person busy. Between recruitment, onboarding and network building, expect around twelve months and a senior salary before qualified pipeline appears.
Fractional business development gives a company a senior BD function part-time, typically one to three days a week, at a lower retainer and with a faster start. It suits small and mid-sized providers that need consistent pipeline but cannot justify a full-time VP of Sales.
A generalist agency is the third option and the weakest for this sector, because it measures activity rather than qualified pipeline and rarely holds a technical conversation credibly.
Frequently asked questions
What does a business developer do in life sciences?
A life sciences business developer defines which accounts the company pursues, creates conversations with named prospects, qualifies them technically as well as commercially, and holds the relationship through cycles that often exceed twelve months.
How is a business developer different from a salesperson?
A salesperson works opportunities that already exist. A business developer decides which market to pursue, creates the opportunities, and carries the relationship before there is anything to close.
How do you measure a business developer in a long sales cycle?
On leading indicators rather than closed revenue: net new named accounts engaged, qualified opportunities created, stage-to-stage conversion, disqualification reasons, and pipeline coverage against quota.
How long before a business developer generates revenue in life sciences?
Plan on around twelve months for a new full-time hire, because recruitment, onboarding and network building precede any qualified pipeline. A defined market and measurable early conversion are reasonable at ninety days.
Does a small CRO or CDMO need a full-time business developer?
Only if demand is steady enough to keep a senior person busy. Below that threshold, a fractional BD arrangement delivers the same function part-time at a lower cost and with a faster start.
Talk to a PharmD-led BD team
Corstrate provides business development for small and mid-sized life sciences service providers in the US and UK markets, led by Imen Jelassi, PharmD, with seventeen years in pharma. If you are deciding between a hire and a fractional arrangement, get in touch.
Comments